Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer

Kayoko Ohnishi, Yoshiyuki Shioyama, Katsumasa Nakamura, Torahiko Nakashima, Saiji Ohga, Takeshi Nonoshita, Tadamasa Yoshitake, Kotarou Terashima, Shizuo Komune, Hiroshi Honda

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Purpose: S-1 is an oral fluoropyrimidine. The purpose of this study was to review the clinical outcomes of S-1 with concurrent radiotherapy for patients with oropharyngeal cancer. Materials and Methods: Between 2002 and 2007, 38 patients with oropharyngeal cancer treated concurrently with S-1 and definitive radiotherapy were reviewed. The clinical stage was Stage I in 4 patients, Stage II in 7, Stage III in 7, and Stage IV in 20. S-1 was administered orally twice daily for 4 consecutive weeks followed by a 2-week drug withdrawal. The initial dose of S-1 was 65 mg/m2/day. All patients were treated using three-dimensional conformal radiotherapy with a median total dose of 65.1 Gy (range, 60.0-71.0 Gy). Clinical outcomes and major acute toxicities were analyzed based on medical records and clinical follow-up. Results: With a median follow-up time of 33 months, the 3-year estimates of local-regional control, distant metastases-free survival, disease-free survival, and overall survival for all patients were 75%, 80%, 65%, and 80%, respectively. The 3-year estimates of local-regional control according to stage were 100% for Stages I and II, 86% for Stage III, and 56% for Stage IV. The rate of ≥ Grade 3 acute mucositis was 32%, and the rate of ≥ Grade 3 hematological toxicities was 8%. No other severe toxicities were observed. Conclusions: Concurrent chemoradiotherapy with S-1 was found to be effective, especially for early disease. The treatment-related toxicities were acceptable, and the incidence of myelotoxicity was low. Further study must be carried out to compare with other chemotherapy regimens.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalJournal of radiation research
Volume52
Issue number1
DOIs
Publication statusPublished - Feb 14 2011

Fingerprint

Oropharyngeal Neoplasms
Chemoradiotherapy
toxicity
cancer
radiation therapy
grade
Radiotherapy
Conformal Radiotherapy
Therapeutics
dosage
Mucositis
metastasis
chemotherapy
estimates
Disease-Free Survival
Medical Records
drugs
incidence
Neoplasm Metastasis
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Radiation
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis

Cite this

Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. / Ohnishi, Kayoko; Shioyama, Yoshiyuki; Nakamura, Katsumasa; Nakashima, Torahiko; Ohga, Saiji; Nonoshita, Takeshi; Yoshitake, Tadamasa; Terashima, Kotarou; Komune, Shizuo; Honda, Hiroshi.

In: Journal of radiation research, Vol. 52, No. 1, 14.02.2011, p. 47-53.

Research output: Contribution to journalReview article

Ohnishi, K, Shioyama, Y, Nakamura, K, Nakashima, T, Ohga, S, Nonoshita, T, Yoshitake, T, Terashima, K, Komune, S & Honda, H 2011, 'Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer', Journal of radiation research, vol. 52, no. 1, pp. 47-53. https://doi.org/10.1269/jrr.10081
Ohnishi, Kayoko ; Shioyama, Yoshiyuki ; Nakamura, Katsumasa ; Nakashima, Torahiko ; Ohga, Saiji ; Nonoshita, Takeshi ; Yoshitake, Tadamasa ; Terashima, Kotarou ; Komune, Shizuo ; Honda, Hiroshi. / Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. In: Journal of radiation research. 2011 ; Vol. 52, No. 1. pp. 47-53.
@article{d203af543f2d49f6bc1a3570d9eb0801,
title = "Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer",
abstract = "Purpose: S-1 is an oral fluoropyrimidine. The purpose of this study was to review the clinical outcomes of S-1 with concurrent radiotherapy for patients with oropharyngeal cancer. Materials and Methods: Between 2002 and 2007, 38 patients with oropharyngeal cancer treated concurrently with S-1 and definitive radiotherapy were reviewed. The clinical stage was Stage I in 4 patients, Stage II in 7, Stage III in 7, and Stage IV in 20. S-1 was administered orally twice daily for 4 consecutive weeks followed by a 2-week drug withdrawal. The initial dose of S-1 was 65 mg/m2/day. All patients were treated using three-dimensional conformal radiotherapy with a median total dose of 65.1 Gy (range, 60.0-71.0 Gy). Clinical outcomes and major acute toxicities were analyzed based on medical records and clinical follow-up. Results: With a median follow-up time of 33 months, the 3-year estimates of local-regional control, distant metastases-free survival, disease-free survival, and overall survival for all patients were 75{\%}, 80{\%}, 65{\%}, and 80{\%}, respectively. The 3-year estimates of local-regional control according to stage were 100{\%} for Stages I and II, 86{\%} for Stage III, and 56{\%} for Stage IV. The rate of ≥ Grade 3 acute mucositis was 32{\%}, and the rate of ≥ Grade 3 hematological toxicities was 8{\%}. No other severe toxicities were observed. Conclusions: Concurrent chemoradiotherapy with S-1 was found to be effective, especially for early disease. The treatment-related toxicities were acceptable, and the incidence of myelotoxicity was low. Further study must be carried out to compare with other chemotherapy regimens.",
author = "Kayoko Ohnishi and Yoshiyuki Shioyama and Katsumasa Nakamura and Torahiko Nakashima and Saiji Ohga and Takeshi Nonoshita and Tadamasa Yoshitake and Kotarou Terashima and Shizuo Komune and Hiroshi Honda",
year = "2011",
month = "2",
day = "14",
doi = "10.1269/jrr.10081",
language = "English",
volume = "52",
pages = "47--53",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "1",

}

TY - JOUR

T1 - Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer

AU - Ohnishi, Kayoko

AU - Shioyama, Yoshiyuki

AU - Nakamura, Katsumasa

AU - Nakashima, Torahiko

AU - Ohga, Saiji

AU - Nonoshita, Takeshi

AU - Yoshitake, Tadamasa

AU - Terashima, Kotarou

AU - Komune, Shizuo

AU - Honda, Hiroshi

PY - 2011/2/14

Y1 - 2011/2/14

N2 - Purpose: S-1 is an oral fluoropyrimidine. The purpose of this study was to review the clinical outcomes of S-1 with concurrent radiotherapy for patients with oropharyngeal cancer. Materials and Methods: Between 2002 and 2007, 38 patients with oropharyngeal cancer treated concurrently with S-1 and definitive radiotherapy were reviewed. The clinical stage was Stage I in 4 patients, Stage II in 7, Stage III in 7, and Stage IV in 20. S-1 was administered orally twice daily for 4 consecutive weeks followed by a 2-week drug withdrawal. The initial dose of S-1 was 65 mg/m2/day. All patients were treated using three-dimensional conformal radiotherapy with a median total dose of 65.1 Gy (range, 60.0-71.0 Gy). Clinical outcomes and major acute toxicities were analyzed based on medical records and clinical follow-up. Results: With a median follow-up time of 33 months, the 3-year estimates of local-regional control, distant metastases-free survival, disease-free survival, and overall survival for all patients were 75%, 80%, 65%, and 80%, respectively. The 3-year estimates of local-regional control according to stage were 100% for Stages I and II, 86% for Stage III, and 56% for Stage IV. The rate of ≥ Grade 3 acute mucositis was 32%, and the rate of ≥ Grade 3 hematological toxicities was 8%. No other severe toxicities were observed. Conclusions: Concurrent chemoradiotherapy with S-1 was found to be effective, especially for early disease. The treatment-related toxicities were acceptable, and the incidence of myelotoxicity was low. Further study must be carried out to compare with other chemotherapy regimens.

AB - Purpose: S-1 is an oral fluoropyrimidine. The purpose of this study was to review the clinical outcomes of S-1 with concurrent radiotherapy for patients with oropharyngeal cancer. Materials and Methods: Between 2002 and 2007, 38 patients with oropharyngeal cancer treated concurrently with S-1 and definitive radiotherapy were reviewed. The clinical stage was Stage I in 4 patients, Stage II in 7, Stage III in 7, and Stage IV in 20. S-1 was administered orally twice daily for 4 consecutive weeks followed by a 2-week drug withdrawal. The initial dose of S-1 was 65 mg/m2/day. All patients were treated using three-dimensional conformal radiotherapy with a median total dose of 65.1 Gy (range, 60.0-71.0 Gy). Clinical outcomes and major acute toxicities were analyzed based on medical records and clinical follow-up. Results: With a median follow-up time of 33 months, the 3-year estimates of local-regional control, distant metastases-free survival, disease-free survival, and overall survival for all patients were 75%, 80%, 65%, and 80%, respectively. The 3-year estimates of local-regional control according to stage were 100% for Stages I and II, 86% for Stage III, and 56% for Stage IV. The rate of ≥ Grade 3 acute mucositis was 32%, and the rate of ≥ Grade 3 hematological toxicities was 8%. No other severe toxicities were observed. Conclusions: Concurrent chemoradiotherapy with S-1 was found to be effective, especially for early disease. The treatment-related toxicities were acceptable, and the incidence of myelotoxicity was low. Further study must be carried out to compare with other chemotherapy regimens.

UR - http://www.scopus.com/inward/record.url?scp=79751495256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751495256&partnerID=8YFLogxK

U2 - 10.1269/jrr.10081

DO - 10.1269/jrr.10081

M3 - Review article

C2 - 21187666

AN - SCOPUS:79751495256

VL - 52

SP - 47

EP - 53

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 1

ER -